title: Clinical predictors of cognitive impairment and psychiatric complications in Parkinson's disease.
abstract: OBJECTIVE
  To estimate the clinical and demographics aspects that may contribute to cognitive impairment and psychiatric symptoms in Parkinson's disease (PD).
  
  
  METHODS
  All patients answered a structured standardized clinical questionnaire. Two movement disorders specialists performed the following scale: Unified Parkinson's disease rating score (UPDRS), the modified Hoehn and Yahr staging, Schwab and England Scale, SCOPA cognition (SCOPA-COG), SCOPA-Psychiatric complications (SCOPA-PC) and Non-Motor Symptoms Scale (NMSS). We built a generalized linear model to assess predictors for the SCOPA-COG and SCOPA-PC scores.
  
  
  RESULTS
  Almost 37% of our patients were demented as per SCOPA-COG scores. Level of education and the UPDRS-Subscale III were predictors of cognitive impairment. Higher scores in domain 3 of NMSS and male gender were associated with psychiatric complications as assessed per the SCOPA-PC.
  
  
  CONCLUSIONS
  Level of education and disease severity are predictors of dementia in PD. Psychiatric complications are more commonly observed in men.
authors.affiliation: Universidade Estadual de Campinas, Campinas, SP, Brazil.
authors.forename: Lidiane S
authors.initials: LS
authors.lastname: Campos
authors.affiliation: Universidade Estadual de Campinas, Campinas, SP, Brazil.
authors.forename: Rachel P
authors.initials: RP
authors.lastname: Guimarães
authors.affiliation: Universidade Estadual de Campinas, Campinas, SP, Brazil.
authors.forename: Luiza G
authors.initials: LG
authors.lastname: Piovesana
authors.affiliation: Universidade Estadual de Campinas, Campinas, SP, Brazil.
authors.forename: Paula C de
authors.initials: PC
authors.lastname: Azevedo
authors.affiliation: Universidade Estadual de Campinas, Campinas, SP, Brazil.
authors.forename: Leonilda M B
authors.initials: LM
authors.lastname: Santos
authors.affiliation: Universidade Estadual de Campinas, Campinas, SP, Brazil.
authors.forename: Anelyssa
authors.initials: A
authors.lastname: D'Abreu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003071:Cognition / Q000502:physiology; D003072:Cognition Disorders / Q000209:etiology* / Q000503:physiopathology; D004522:Educational Status; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000209:etiology* / Q000503:physiopathology; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics; D012307:Risk Factors; D012720:Severity of Illness Index; D012737:Sex Factors
chemical_list: D000978:Antiparkinson Agents